Preclinical studies across various cancer types suggest that TREM2 is a promising therapeutic target for cancer immunotherapy.In non-small cell lung cancer (NSCLC), TREM2+ TAMs are enriched in immunologically “cold” tumors and correlate with poor response to anti–PD-1 therapy. Here, TREM2 is linked to non-small cell lung carcinoma.